Rheumatism treatment effective even when the use of biological agents is slightly delayed

December 5, 2013, Medical University of Vienna
Rheumatism treatment effective even when the use of biological agents is slightly delayed

The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents where necessary. These are the findings of a study, led by Josef Smolen, Director of the Clinical Department of Rheumatology at the Medical University of Vienna, which has now been published in the highly respected journal The Lancet.  

In the randomised OPTIMA study, the scientists discovered that six months of treatment with the most common anti-rheumatoid drug Methotrexate and subsequent with a biological agent in who did not respond adequately to Methotrexate produced results that were just as good as those obtained in patients who were given combined Methotrexate and biological agent treatment right from the start. Says Smolen: "The crucial factor, however, is that the biological agent therapy – which in this case involved the tumour necrosis factor blocker Adalimumab – is added relatively quickly after the failure of Methotrexate, i.e. around six months later. Moreover, the patients in this study had a high risk of severe progression of their rheumatoid arthritis."

Paradigm shift in the treatment of rheumatoid arthritis?

The team led by Josef Smolen, who is the third most-quoted rheumatology expert in the world, also discovered that it should be possible, in cases of the early use of combination therapy involving the biological agent with Methotrexate, to discontinue the after six months if low has been achieved and still be able to maintain this status.

Says Smolen: "The option of switching the combination therapy back to non-biological treatment would be a in the of rheumatoid arthritis, however more studies along the same lines are needed to confirm this."

The large, 18-month study involved a cohort of around 1,000 high-risk patients from 161 locations who had high disease activity, increased risk of infection and joint swelling. This high level of disease activity affects just under 50 per cent of patients with rheumatoid arthritis. Around three to five per cent of the population has inflammatory rheumatism (in Austria, this equates to around 250,000 to 400,000 people) and around 1% have rheumatoid arthritis (around 80,000 people in Austria).

The paper has been published in the world-leading journal The Lancet and has also received praise: "We believe that the study was an excellent one; it has been meticulously analysed and interpreted correctly. We would like to congratulate Josef Smolen and his team for tackling the problem of from a very different perspective," says the editorial in the magazine, which has an impact factor of 39.

Explore further: Rheumatism drug also effective at half dose

More information: "Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial". Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald F van Vollenhoven, Karel Pavelka, Patrick Durez, Benoît Guérette, Hartmut Kupper, Laura Redden, Vipin Arora, Arthur Kavanaugh. The Lancet, published online October 26, 2013. dx.doi.org/10.1016/S0140-6736(13)61751-1

Related Stories

Rheumatism drug also effective at half dose

January 18, 2013
The treatment of moderately active rheumatoid arthritis with the tumour necrosis factor inhibitor Etanercept achieves excellent success in more than 80 per cent of patients. With this method, the success can be maintained ...

The effect on work loss of different treatments for rheumatoid arthritis

July 1, 2013
Treatment with a biological agent was not superior to conventional treatment in terms of the effect on work loss over 21 months in patients with early rheumatoid arthritis (RA) who responded insufficiently to methotrexate, ...

Treating rheumatoid arthritis early may cut damaging effects

October 28, 2013
(HealthDay)—Immediate and effective treatment for rheumatoid arthritis reduces the risk that patients will have joint damage and disability within a few years, a new study suggests.

Rheumatoid arthritis and heart disease: Studies shed light on dangerous connection

October 26, 2013
People with rheumatoid arthritis and other chronic inflammatory conditions are at higher risk of heart disease. Who is in the most danger, why and how best to prevent and detect cardiovascular complications are important ...

Expensive or not, rheumatoid arthritis drugs have similar effect: study

July 1, 2013
(HealthDay)—Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds.

Genomic study: Why children in remission from rheumatoid arthritis experience recurrences

August 29, 2013
More children with juvenile rheumatoid arthritis are experiencing remission of their symptoms, thanks to new biological therapies, but the remission is not well-understood. A new study published today in Arthritis Research ...

Recommended for you

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

November 20, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.

Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was ...

Study lists foods for fighting rheumatoid arthritis symptoms and progression

November 8, 2017
A list of food items with proven beneficial effects on the progression and symptoms of rheumatoid arthritis is provided in a new study published today in Frontiers in Nutrition. The authors suggest incorporating these foods ...

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.